Schizophrenia

The FDA has accepted a new drug application from Karuna Therapeutics for KarXT, an investigational muscarinic antipsychotic for the treatment of schizophrenia in adults, the company announced in a press release.

Brilaroxazine, a potential new treatment for schizophrenia, significantly improved symptoms and was well-tolerated in a pivotal phase 3 trial, according to a press release from its manufacturer.

An earlier follow-up visit after psychiatric inpatient discharge was associated with lower risk of suicide in a population-based study from South Korea.

Karuna Therapeutics Inc. has submitted a new drug application to the FDA for KarXT, its investigational muscarinic antipsychotic for the treatment of schizophrenia.

A woman diagnosed with schizophrenia and psychosis who was nonverbal and nonresponsive for 2 decades recently “woke” after treatment with pulse steroids and cyclophosphamide.

Healio compiled the most-read news in allergy, asthma and immunology posted in August.

Atopic dermatitis was associated with increased odds for schizophrenia and schizoaffective disorder, according to a study published in Archives of Dermatological Research.

Two phase 3 studies of a once-daily treatment for schizophrenia failed to meet their primary endpoints, with developers pointing to placebo effects and disruption from the COVID-19 pandemic to possibly explain the drug’s performance.

BOSTON — With a multitude of products spanning neuroscience and psychiatry, executives at AbbVie say they are committed to learning the full clinical value of all of the company’s products for the benefit of patients.

Symptom dimensions within bipolar disorder may have distinct causes, supporting the hypothesis that genetic heterogeneity underpins clinical heterogeneity, according to a study published in The Lancet Psychiatry.